XML 57 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Share equity incentive plans (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of options activity
The following table summarizes share option activity for the years ended December 31, 2020 and 2021 :
December 31,
20202021
Number
of
Options		Weighted-Average Exercise PriceWeighted-
Average remaining Contractual Term
(in years)		Number
of
Options		Weighted-Average Exercise PriceWeighted-
Average remaining Contractual Term
(in years)
Outstanding at the beginning of the year9,887,125 $1.77 6.409,874,165 $1.99 6.83
Granted2,581,893 2.56 — 1,708,500 3.71 — 
Exercised(1,656,994)0.87 — (1,301,233)0.94 — 
Forfeited(937,859)3.22 — (300,038)3.71 — 
Outstanding at the end of the year9,874,165 $1.99 6.839,981,394 $2.37 6.65
Exercisable at the end of the year5,624,558 $1.58 5.306,150,329 $1.99 5.54
Schedule of valuation assumptions
The fair value of these options was estimated on the grant date based on the following assumptions:
December 31,
201920202021
Volatility50%50%60%
Expected term in years6.256.256.25
Risk-free interest rate
1.55%-2.54%
0.12% - 1.47%
0.55% -0.92%
Estimated fair value of underlying ordinary shares
2.17-3.44
3.34 - 7.6
12.92- 24.08
Dividend yield0%0%0%
Schedule of options by exercise price
The following table summarizes information about share options outstanding under the 2012 Plan and 2021 Plan as of December 31, 2020 and 2021:
Options OutstandingOptions Exercisable
Number Outstanding at December 31, 2020Weighted Average Remaining Contractual Life (Years)Number Exercisable at December 31, 2020Weighted Average Remaining Contractual Life (Years)
$0.0003589,000 2.58589,000 2.58
$0.01355,700 9.85— 0
$0.401,264,241 3.181,264,241 3.18
$0.6069,286 4.4669,286 4.46
$0.652229,521 0.16229,521 0.16
$1.43401,500 9.71— 0
$1.90738,530 4.74738,530 4.74
$2.171,604,121 7.121,134,964 7.01
$2.25126,224 5.70126,224 5.70
$2.388566,900 9.81— 0
$2.712,761,792 7.991,353,667 7.94
$3.44302,250 8.7292,125 8.68
$3.57775,500 9.6027,000 9.34
$5.9789,600 9.91— 0
Total9,874,165 6.835,624,558 5.30
Aggregate intrinsic value$55,419 $33,818 
Options OutstandingOptions Exercisable
Number Outstanding at December 31, 2021Weighted Average Remaining Contractual Life (Years)Number Exercisable at December 31, 2021Weighted Average Remaining Contractual Life (Years)
$0.000389,000 1.5889,000 1.58
$0.01355,700 8.85155,618 8.85
$0.401,149,241 2.051,149,241 2.05
$0.6065,286 3.4565,286 3.45
$1.43401,500 8.71125,468 8.71
$1.90594,320 3.73594,320 3.73
$2.171,396,871 6.151,235,090 6.12
$2.25117,224 3.24117,224 3.24
$2.388489,700 8.69129,400 8.19
$2.712,655,489 6.851,936,746 6.76
$3.041,401,700 9.08131,250 9.08
$3.44248,501 7.36140,191 6.98
$3.57748,562 8.60261,308 8.54
$5.9779,500 8.9120,187 8.91
$7.60184,800 9.08— 0
$24.084,000 9.61— 0
Total9,981,394 6.656,150,329 5.54
Aggregate intrinsic value$155,136 $97,907 
Schedule of RSU activity
The following table summarizes RSU activity for the years ended December 31, 2020 and 2021:
December 31,
2020		The weighted average fair value at grant dateDecember 31,
2021		The weighted average fair value at grant date
(Number of units)(Number of units)
Outstanding at the beginning of the year
— $— 132,500 $7.60 
Granted132,500 7.60 880,022 20.41 
Vested— — (10,354)11.15 
Forfeited— — (34,371)14.46 
Outstanding at the end of the year
132,500 7.60 967,797 18.97 
Unvested RSUs132,500 7.60 967,797 18.97 
Schedule of expenses capitalized
The following table summarizes the share-based compensation, including the share-based compensation of the secondary transactions described in Note 12, recorded in each line item in the accompanying consolidated states of comprehensive income (loss):
Year Ended December 31,
201920202021
Cost of revenue$38 $40 $211 
Research and development452 1,107 4,058 
Sales and marketing427 821 3,450 
General and administrative1,087 2,832 3,452 
Total$2,004 $4,800 $11,171